^
Association details:
| Biomarker: | ALK rearrangement + MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)
Published date:
08/21/2020
Excerpt:
A total 132 patients with ALK rearrangement advanced NSCLC from 4 centers in Guangdong province, China were evaluated. All patients received crizotinib treatment...Among the 132 patients, 12.1% (16/132) patients had concomitant oncogene mutations (EGFR, ERBB2, KRAS, BRAF, MET, RET, ROS1, or PIK3CA), including 3 (2.3%) patients with EGFR mutations, 4 (3.0%) with ERBB2 mutations, 1 (0.76%) with KRAS mutations, 4 (3.0%) with MET amplification, and 4 (3.0%) with PI3KCA mutations...In patients with and without oncogene mutations, median PFS values were 4.9 months (95% CI 3.3–8.6) and 12.9 months (95% CI 11.9–16.8), respectively (HR 2.825; 95% CI 1.559–5.118; P = 0.0003)...
DOI:
10.3389/fonc.2020.01216
